In Reply to the Letter to the Editor from Raj et al.: Clinical Evidence Indicates Allogeneic Mesenchymal Stem Cells Do Not Pose a Significant Risk for Cancer Progression in the Context of Cell-Based Drug Delivery. Stem Cells Transl Med. 2019.
LEF1 Targeting EMT in Prostate Cancer Invasion is Regulated by miR-34a. Mol Cancer Res. 2015.